NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Stock Information for iBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iBio Inc.

NuCana Prices $7 Million Registered Direct Offering
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
NuCana to Present at the Jefferies Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.